Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 369

1.

The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.

Eralp Y.

Transl Oncogenomics. 2016 Aug 14;8(Suppl 1):1-7. doi: 10.4137/TOG.S39410. eCollection 2016. Review.

2.
3.

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.

Miller CA, Gindin Y, Lu C, Griffith OL, Griffith M, Shen D, Hoog J, Li T, Larson DE, Watson M, Davies SR, Hunt K, Suman VJ, Snider J, Walsh T, Colditz GA, DeSchryver K, Wilson RK, Mardis ER, Ellis MJ.

Nat Commun. 2016 Aug 9;7:12498. doi: 10.1038/ncomms12498.

4.

EGFR and SYNE2 are associated with p21 expression and SYNE2 variants predict post-operative clinical outcomes in HBV-related hepatocellular carcinoma.

Han C, Liao X, Qin W, Yu L, Liu X, Chen G, Liu Z, Lu S, Chen Z, Su H, Zhu G, Lu Z, Liu Z, Qin X, Gui Y, Mo Z, Li L, Peng T.

Sci Rep. 2016 Aug 9;6:31237. doi: 10.1038/srep31237.

5.

Classical pathology and mutational load of breast cancer - integration of two worlds.

Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz JK, Györffy B, Dietel M, Loibl S, Weichert W, Stenzinger A.

J Pathol Clin Res. 2015 Jul 20;1(4):225-38. doi: 10.1002/cjp2.25. eCollection 2015 Oct.

6.

Anti-androgen therapy in triple-negative breast cancer.

Barton VN, Gordon MA, Richer JK, Elias A.

Ther Adv Med Oncol. 2016 Jul;8(4):305-8. doi: 10.1177/1758834016646735. Epub 2016 May 31. No abstract available.

7.

New generation of breast cancer clinical trials implementing molecular profiling.

Zardavas D, Piccart-Gebhart M.

Cancer Biol Med. 2016 Jun;13(2):226-35. doi: 10.20892/j.issn.2095-3941.2015.0099.

8.

Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge.

Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A.

PLoS One. 2016 Jul 8;11(7):e0159072. doi: 10.1371/journal.pone.0159072. eCollection 2016.

9.

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA.

PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

10.

Triple-negative breast cancer: treatment challenges and solutions.

Collignon J, Lousberg L, Schroeder H, Jerusalem G.

Breast Cancer (Dove Med Press). 2016 May 20;8:93-107. doi: 10.2147/BCTT.S69488. eCollection 2016.

11.

A microscopic landscape of the invasive breast cancer genome.

Ping Z, Xia Y, Shen T, Parekh V, Siegal GP, Eltoum IE, He J, Chen D, Deng M, Xi R, Shen D.

Sci Rep. 2016 Jun 10;6:27545. doi: 10.1038/srep27545.

12.

Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies.

Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA.

Cancer Res. 2016 Aug 15;76(16):4850-60. doi: 10.1158/0008-5472.CAN-16-0058. Epub 2016 May 26.

PMID:
27231203
13.

Analysis of Paired Primary-Metastatic Hormone-Receptor Positive Breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.

Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, Rubio-Camarillo M, Rodriguez-Peralto JL, Pujana MA, Pisano DG, Quintela-Fandino M.

PLoS One. 2016 May 19;11(5):e0155840. doi: 10.1371/journal.pone.0155840. eCollection 2016.

14.

Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.

Gautam P, Karhinen L, Szwajda A, Jha SK, Yadav B, Aittokallio T, Wennerberg K.

Mol Cancer. 2016 May 10;15(1):34. doi: 10.1186/s12943-016-0517-3.

15.

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Pereira B, Chin SF, Rueda OM, Vollan HK, Provenzano E, Bardwell HA, Pugh M, Jones L, Russell R, Sammut SJ, Tsui DW, Liu B, Dawson SJ, Abraham J, Northen H, Peden JF, Mukherjee A, Turashvili G, Green AR, McKinney S, Oloumi A, Shah S, Rosenfeld N, Murphy L, Bentley DR, Ellis IO, Purushotham A, Pinder SE, Børresen-Dale AL, Earl HM, Pharoah PD, Ross MT, Aparicio S, Caldas C.

Nat Commun. 2016 May 10;7:11479. doi: 10.1038/ncomms11479.

16.

Tree inference for single-cell data.

Jahn K, Kuipers J, Beerenwinkel N.

Genome Biol. 2016 May 5;17:86. doi: 10.1186/s13059-016-0936-x.

17.

Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers.

Laskin J, Jones S, Aparicio S, Chia S, Ch'ng C, Deyell R, Eirew P, Fok A, Gelmon K, Ho C, Huntsman D, Jones M, Kasaian K, Karsan A, Leelakumari S, Li Y, Lim H, Ma Y, Mar C, Martin M, Moore R, Mungall A, Mungall K, Pleasance E, Rassekh SR, Renouf D, Shen Y, Schein J, Schrader K, Sun S, Tinker A, Zhao E, Yip S, Marra MA.

Cold Spring Harb Mol Case Stud. 2015 Oct;1(1):a000570. doi: 10.1101/mcs.a000570.

18.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 May 2;534(7605):47-54. doi: 10.1038/nature17676.

PMID:
27135926
19.

Exosomes: The Link between GPCR Activation and Metastatic Potential?

Isola AL, Chen S.

Front Genet. 2016 Apr 8;7:56. doi: 10.3389/fgene.2016.00056. eCollection 2016. Review.

20.

Intratumoral Heterogeneity of the Epigenome.

Mazor T, Pankov A, Song JS, Costello JF.

Cancer Cell. 2016 Apr 11;29(4):440-51. doi: 10.1016/j.ccell.2016.03.009. Review.

PMID:
27070699
Items per page

Supplemental Content

Write to the Help Desk